Conditions: Hypertension
Keywords: Post Menopause Female Obese
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 21
Healthy volunteers: no

Brief summary:
The purpose of the research is to evaluate the effect of azilsartan medoximil on blood pressure and urinary aldosterone levels in postmenopausal females.

Detailed description:
The study is a randomized, placebo-controlled trial of post-menopausal females with stage 1 hypertension. The goal is to randomize 40 post-menopausal females with stage 1 hypertension and assess whether azilsartan reduces urinary aldosterone levels. We will compare subjects having azilsartan medoximil (treatment group) with placebo group. Additionally, a small sub-study comparing pre-menopausal and post-menopausal female aldosterone levels was performed as well as the presence of aldosterone production in fat cell cultures of a subset of 3 patients in the randomized trial.

Arms:
arm 1: Subjects randomized to azilsartan medoximil arm will take 80 mg of azilsartan medoximil tablets by mouth each day. arm 2: Subjects randomized to the placebo arm will take 80 mg of placebo tablets by mouth each day

Interventions: intervention 1: Azilsartan medoximil intervention 2: Placebo
Intervention descriptions: intervention 1: All subjects were randomized to 80mg azilsartan medoxomil (azilsartan) daily or placebo and followed for six months. intervention 2: All subjects were randomized to 80mg azilsartan medoxomil (azilsartan) daily or placebo and followed for six months.

Protocol document: